deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02073968

PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II-IV Non-small Cell Lung Cancer (PAINT)

PET-Adjusted IMRT for NSCLC Trial (PAINT)

Sponsor: Albert Einstein College of Medicine

Conditions Metastatic Malignant Neoplasm in the Brain Recurrent Non-Small Cell Lung Carcinoma Stage IIA Non-Small Cell Lung Carcinoma Stage IIB Non-Small Cell Lung Carcinoma Stage IIIA Non-Small Cell Lung Cancer Stage IIIB Non-Small Cell Lung Cancer Stage IV Non-Small Cell Lung Cancer
Interventions Carboplatin Computed Tomography Intensity-Modulated Radiation Therapy Paclitaxel Positron Emission Tomography Proton Beam Radiation Therapy
Updated 16 times since 2017 Last updated: Jan 23, 2024 Started: Jul 31, 2013 Primary completion: Dec 31, 2017 Completion: Nov 30, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02073968, this PHASE2 trial focuses on Metastatic Malignant Neoplasm in the Brain and Recurrent Non-Small Cell Lung Carcinoma and remains completed. Sponsored by Albert Einstein College of Medicine, it has been updated 16 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Apr 2018 · 9 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshot~Feb 2019 – ~Feb 2020 · 12 months · monthly snapshot~Feb 2020 – ~Dec 2020 · 10 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Feb 2022 · 2 months · monthly snapshot~Feb 2022 – ~Jan 2023 · 11 months · monthly snapshot~Jan 2023 – ~Feb 2024 · 13 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Feb 2024 — Jul 2024 [monthly]

    Completed PHASE2

  5. Jan 2023 — Feb 2024 [monthly]

    Completed PHASE2

▶ Show 11 earlier versions

  1. Feb 2022 — Jan 2023 [monthly]

    Completed PHASE2

  2. Dec 2021 — Feb 2022 [monthly]

    Completed PHASE2

  3. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  4. Dec 2020 — Jan 2021 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  5. Feb 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE2

  6. Feb 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE2

  7. Jun 2018 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  8. Apr 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

  9. Jul 2017 — Apr 2018 [monthly]

    Active Not Recruiting PHASE2

  10. Feb 2017 — Jul 2017 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  11. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Albert Einstein College of Medicine
  • National Cancer Institute (NCI)
Data source: Albert Einstein College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations